Ovarian cancer is an extremely aggressive disease associated with a high percentage of tumor recurrence and chemotherapy resistance. Understanding the underlying mechanism of tumor relapse is crucial for effective therapy of ovarian cancer. DNA damage binding protein 2 (DDB2) is a DNA repair factor mainly involved in nucleotide excision repair. Here a novel role was identified for DDB2 in the tumorigenesis of ovarian cancer cells and the prognosis of ovarian cancer patients. Overexpressing DDB2 in human ovarian cancer cells suppressed its capability to recapitulate tumors in athymic nude mice.
Introduction
of tumor relapse (15) . Thus, there is an urgent need for detailed characterization of these CSCs in order to device new treatment modalities.
DDB2 is a 48-kDa protein originally identified as a component of the damage-specific DNA-binding heterodimeric complex DDB (16) . DDB2 is able to bind UV-damaged DNA and serves as the initial damage recognition factor during nucleotide excision repair (NER) (17) . The low expression of DDB2 in cisplatin-resistant ovarian cancer cell lines (18) and high-grade colon cancer (19) and skin cancer (20) indicates a link between DDB2 expression and tumor progression. Recently new functions of DDB2 beyond its role in DNA repair have been identified, e.g., inhibiting cellular apoptosis through downregulation of Bcl-2 (18, 21) , and p21 (22) , suppressing colon tumor metastasis through blocking epithelial-mesenchymal transition (EMT) (19) , and limiting the motility and invasiveness of invasive human breast tumor cells by regulating NFκB activity (23) , as well as mediating premature senescence (24) . In this study, we reveal a novel role of DDB2 in the inhibition of tumorigenesis. DDB2 overexpression resulted in a reduction of the CSC population associated with repression of the tumorigenicity of ovarian cancer cells, whereas DDB2 knockdown resulted in an expansion of the CSC population.
Richard Allen hematoxylin. Intensity of staining was blind scored from 1 (no staining) to 4 (highest intensity of staining).
Plasmids and gene transfection
pReceiver-Lv105-DDB2 (GeneCopoeia, Rockville, MD) and pcDNA3.1-His-DDB2 plasmids were introduced into cells by using either lentivirus infection or electroporation with NEPA-21 Electroporator (Nepa Gene Co., Ltd, Chiba, Japan). DDB2 expression lentiviruses were generated as described before (21) . To establish shDDB2 stably transfected cell lines, MISSION shDDB2 (TRCN0000083993) plasmids (Sigma) were transfected into 2008 cells using eletroporation. The transfected cells were selected in the medium containing 2 µg/ml Puromycin, and the transfectant lines with stable DDB2 downregulation were confirmed by Western blotting.
Immunoblotting
Whole cell lysates were prepared by boiling cell pellets for 10 min in SDS lysis buffer [2% SDS, 10%
Glycerol, 62 mM Tris-HCl, pH 6.8 and a complete mini-protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN)]. After protein quantification with Bio-Rad Dc Protein Assay (Bio-Rad Laboratories, Hercules, CA), equal amounts of proteins were loaded, separated on a polyacrylamide gel, and transferred to a nitrocellulose membrane. Protein bands were immuno-detected with appropriate antibodies, e.g., goat anti-DDB2 (R&D Systems, Minneapolis, MN), rabbit anti-Nanog (Cell Signaling Technology, Danvers, MA), mouse anti-Tubulin (Millipore, Billerica, MA), and mouse-anti-IκBα (Cell Signaling Technology, Danvers, MA).
Semisolid colony forming assay
Cells were trypsinized and counted. 1,000 cells were mixed with semisolid media (MethoCult H4100, STEMCELL Technologies Inc, Vancouver, Canada) containing serum-free DMEM/F12 (Life Technologies, Grand Island, NY) supplemented with 20% KnockOut Serum Replacement (Life Technologies), 20 ng/ml EGF (Life Technologies), 10 ng/ml bFGF (Life Technologies), 100 μg/ml streptomycin and 100 units/ml penicillin (Life Technologies), and seeded in 6-well Ultra-Low Attachment plates (Corning, Lowell, MA). The number of larger (more than 50 cells), symmetric and prototypical colonies was counted after 6 days.
Flow cytometry analysis and cell sorting
Anti-CD117-PE and anti-CD44-FITC (BD Pharmingen, San Diego, CA) were used for flow cytometric analysis and cell sorting. Detection of ALDH activity was conducted using the ALDEFLUOR supplemented with 20% KnockOut Serum Replacement, 20 ng/ml EGF, 10 ng/ml bFGF, 100 μg/ml streptomycin and 100 units/ml penicillin. Cells were grown at 37°C in humidified atmosphere of 5% CO 2 in air.
Isolation of putative CSCs based on sphere formation
CSCs are able to form colonies from a single cell more efficiently than their progeny (27) and to grow as spheres in non-adherent culture conditions (28) . We seeded SKOV3 cells in Ultra-Low attachment 96-well plate by serial dilution, and cultured them in 100 µl KnockOut DMEM/F12 medium supplemented with 20% KnockOut Serum Replacement, 20 ng/ml EGF and 10 ng/ml bFGF. 10 µl of fresh medium was added every 2 days. After 1 month, wells that contain just a single colony were marked. These SKOV3-spheroids were then subcultured from the wells into larger vessels for further growing and defined as putative CSCs.
Sphere-forming assay
1,000 of CSCs were plated in triplicate in Ultra-Low attachment plates in serum-free DMEM/F12 medium supplemented with serum replacement, EGF and bFGF. Sphere formation was assessed 2 weeks after cell seeding. Spheres are defined as floating non-adherent multicellular cell aggregates.
Quantitative RT-PCR
Total RNA was extracted using Trizol reagent (Invitrogen), and the first strand cDNA was generated Tumor growth curves were compared using a Student's t test.
Statistical analysis
Student's t test and Non-Parametrics Mann-Whitney test were performed for data analysis by using Minitab software. Log-rank analysis was used to determine statistical significance of Kaplan-Meier survival curve. For all statistical methods, P < 0.05 was considered statistically significant. 
Results

DDB2 is downregulated in ovarian cancers
It has been reported that DDB2 protein expression is downregulated in human colon cancer and skin cancer demonstrated by immunohisochemical (IHC) staining (19, 20) . To determine the DDB2 protein expression level in primary ovarian carcinoma, we constructed TMA and analyzed DDB2 expression using IHC with an antibody specific for DDB2. IHC staining of the samples showed that normal ovary epithelial cells exhibit strong DDB2 staining, while ovarian carcinoma cells in most of tumor tissue samples display low DDB2 expression (Fig. 1A) . Statistical analysis revealed a significant decrease of DDB2 expression in ovarian carcinomas regardless the grade (Fig. 1B) , indicating a strong correlation between the loss of DDB2 expression and the ovarian carcinoma.
DDB2 represses tumorigenicity of ovarian cancer cells in vivo and in vitro
To further investigate the role of DDB2 in the tumorigenicity of ovarian cancer cells, we overexpressed DDB2 in cisplatin-resistant ovarian cancer cell line CP70, which expresses low level of endogenous DDB2 (18) , and established two stable cell lines with DDB2 overexpression (Fig. 2A, left panel). We also transfected DDB2 shRNA into another ovarian cancer cell line 2008 and selected two stable DDB2-knockdown cell lines ( Fig. 2A, right panel) . We then assessed the anchorage-independent growth of these cells in vitro by culturing them in semisolid serum-free medium. As shown in Fig final tumor sizes also indicate that DDB2 overexpression suppresses the growth of implanted human ovarian cancer cells (Fig. 2F,G) . Taken together, these in vitro and in vivo data indicate that DDB2 is able to suppress tumorigenicity of ovarian cancer cells.
DDB2 overexpression reduces the CSC subpopulation in ovarian cancer cells
It has recently been reported that DDB2 suppresses the tumorigenicity and invasiveness of colon cancer cells through suppressing EMT (19) . We then analyzed the EMT markers in CP70 cells with or without overexpression of DDB2. We were unable to find any effect of DDB2 overexpression on the cellular levels of epithelial marker E-Cadherin and mesenchymal marker Vimentin ( Supplementary Fig.   S1A ). In addition, we failed to see any change in morphology of the cells with DDB2 overexpression Fig. S4A,B) . Besides ALDH activity, CD44 + CD117 + was also used as a phenotypic marker of ovarian CSCs (5). We then sought to determine whether DDB2 Fig. S6A, B) . Collectively, these results indicate that DDB2 is able to reduce the CSCs pool existing in ovarian cancer cells.
Ovarian CSCs exhibit low DDB2 expression level
To elucidate the mechanism of the DDB2-mediated regulation of the CSC population, we isolated the 
DDB2 inhibits the self-renewal property and tumorigenicity of ovarian CSCs through suppressing NF-κB pathway
To further investigate whether low DDB2 expression is required to maintain the stem cell properties of ovarian CSCs, we transfected DDB2-expressing plasmids into three ovarian CSC populations and analyzed the expression of stem cell marker Nanog and their capability to form spheres in non-adherent culture condition. As shown in Fig. 5A -C, overexpression of DDB2 was accompanied by a reduced Nanog expression in all three CSCs. In addition, DDB2 overexpression significantly reduced the CSCs' capability to form floating spheres in serum-free medium (Fig. 5D-F) .
These data indicate that DDB2 is able to disrupt the self-renewal property of ovarian CSCs. 
cancer cell lines. We then transiently transfected DDB2 into 2008C13-CD44
+ CD117 + cells and SKOV3-spheroids, and found that overexpression of DDB2 also increased the expression of IκBα in both ovarian CSC populations (Fig. 5J ). This data indicates that DDB2-mediated reduction of ovarian CSC population could be attributed, at least in part, to the DDB2-induced upregulation of IκBα, which results in the inactivation of NF-κB pathway.
Low DDB2 mRNA expression level correlates with poor prognosis of ovarian cancer patients
Our data from the studies in vitro and in vivo indicates that loss of DDB2 is associated with highly tumorigenic potential in ovarian cancer cells. In order to understand whether there is any relationship between the level of DDB2 expression and the prognosis in human ovarian cancer patients, we evaluated publicly available datasets for DDB2 mRNA expression (Supplementary materials and methods). First, we used an online tool (http://kmplot.com) to assess the prognostic value of the Microarray-quantified DDB2 expression level in ovarian cancer patients included in ten datasets (36) . Kaplan-Meier survival curves showed that low DDB2 mRNA expression correlates with poor overall and progression-free survival (PFS) among ovarian cancer patients (Fig. 6A,B) . We then used another online tool cBioPortal (http://cbioportal.org) to analyze the effect of extremely low DDB2 expression or high DDB2 expression on the overall survival of ovarian cancer patients from The Cancer Genome Atlas (TCGA) data portal (37) (38) (39) . Similarly, the Kaplan-Meier survival analyses demonstrated that ovarian cancer patients with DDB2 mRNA expression Z-score less than -2 exhibited poor prognosis compared to those patients with DDB2 expression Z-score greater than -2 (median survival months: 26.94 vs. 44.29), while the patients with DDB2 expression Z-score higher than 0.5 exhibited better prognosis than those with DDB2 expression Z-score less than 0.5 (median survival months: 55.88 vs. 41.53) (Fig. 6C,D) . However, while the TCGA dataset demonstrates that overall survival is different, there is no difference in PFS. These analyses suggest that DDB2 low expression is associated with poor outcome in ovarian cancer patients.
Discussion
Despite significant advances in diagnosing and treating ovarian cancer, one of the major clinical and scientific problems that remain unresolved is the prediction and inhibition of ovarian tumor recurrence after clinical remission. In the present study, we provide evidence showing that low DDB2 expression is correlated with poor outcome of ovarian cancer patients, overexpression of DDB2 in ovarian cancer cells reduces their tumorigenicity through limiting the CSC population, thus defining a novel function for DDB2 in the control of tumor relapse. DDB2 has been considered a tumor suppressor based on the findings that DDB2-/-mice were not only susceptible to UV-induced carcinogenesis, but also developed spontaneous malignant tumors at a high rate (40, 41) . The analysis of publicly available datasets in this study indicates that low DDB2 mRNA expression correlates with poor outcome of ovarian cancer patients.
Indeed, this kind of correlation can also be found in breast (23) and lung cancer patients (http://www.kmplot.com). Therefore, in combination with our findings in this study and others (19) , we believe that DDB2 plays an important role in impeding tumor progression and tumor relapse.
DDB2 has been reported to inhibit metastasis of colon cancer (19) and limit the invasiveness of breast cancer (23) . Mechanistically, DDB2 constitutively represses genes that are the key activators of EMT through its transcriptional regulation function in various colon cancer cell lines (19) . In addition, DDB2
attenuates the activity of NF-κB by upregulating expression of IκB in breast cancer cells. EMT is believed to be a crucial mechanism for tumor metastatic progression (42), while NF-κB plays a causal role in migration and invasion of tumor cells and is required for maintenance of the malignant phenotype (43) .
Thus, the DDB2-dependent decrease of EMT and NF-κB activity could explain in part the correlation between high DDB2 expression and an improvement of the outcome in cancer patients. Besides these known mechanisms, we demonstrated for the first time in this study that DDB2 is able to reduce the abundance of CSCs in the bulk ovarian cancer cells, which provide a novel mechanism to explain the (43), a process that can be used by cancer cells to reacquire "stemness". Thus, it seems possible that DDB2 reduces the abundance of CSC through inhibiting NFκB-mediated EMT. Indeed, it has been reported that DDB2 is able to suppress EMT by constitutively repressing genes that are the key activators of EMT in colon cancer (24) . However, we failed to find the alterations of epithelial marker E-Cadherin and mesenchymal marker Vimentin in ovarian cancer cells after DDB2 overexpression or knockdown.
Therefore, we incline to the mechanism that DDB2 reduces the CSC subpopulation through shutting down the pathways required for the maintenance of CSCs.
The cellular level of DDB2 could be regulated at both transcript level and protein levels. According to the publicly available TCGA datasets, 16.5% (52/316) ovarian cancer patients display downregulated DDB2 mRNA (Z-score < -1), while 8.5% (27/316) display DDB2 mRNA upregulation (Z-score > 1) (www.cbioportal.org). Similarly, downregulation of the DDB2 mRNA can also be found in majority of the colon carcinoma datasets (24) . In ovarian cancer datasets, heterozygous deletion contributes partially to the downregulation of DDB2 mRNA, while promoter CpG methylation seems not a determinant of DDB2 mRNA expression ( Supplementary Fig. S11 ) (www.cbioportal.org). At the protein level, DDB2 
can be ubiquitylated by DDB-Cul4A ubiquitin ligase, and its ubiquitylation and subsequent degradation are essential for its functions in NER (47, 48) . DDB2 is also ubiquitylated in human cells in the absence of exogenous DNA damage (49) , indicating that the steady-state level of DDB2 can be regulated by posttranslational modification. Furthermore, DDB2 protein stability is reported to be regulated by USP24, a deubiquitylating enzyme, by removing the ubiquitin moiety from modified DDB2, thereby preventing DDB2 degradation (50) . We found in this study that CSCs display reduced DDB2 protein level but not mRNA level in comparison with their parental bulk cancer cells. Thus, it is more likely that ovarian CSCs regulate the cellular DDB2 expression by decreasing its protein stability, and the underlying mechanisms warrants a further investigation in the future.
In conclusion, we report here a novel function of DDB2 in limiting tumorigenicity of ovarian cancer cells. Overexpression of DDB2 is able to inhibit the self-renewal ability of ovarian CSCs, probably through inhibiting NFκB pathway, leading to a reduction of CSC subpopulation, and finally results in an impediment of tumor progression. 
